DEVONIAN HEALTH GROUP INC.

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Health Group to present at GCFF (Global Chinese Financial Conference) 18th annual conference.

Quebec, Quebec – September 12, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSX VENTURE: GSD) a clinical stage botanical pharmaceutical corporation, today announced that the Company’s President and Chief Executive Officer, Dr. Andre P. Boulet, will present an overview of the Company at the upcoming GCFF 18th Annual Conference on Saturday, September 30th at the Courtyard & Towneplace Suites, 7095 Woodbine Avenue, Markham, Ontario.

“We are pleased to participate in this world class conference that will allow us to share our recent developments and explore potential trade avenues with a respected group of Chinese stakeholders. With the recent announcement of the Canadian Dermatology Association’s recognition of our first product in the commercialization phase and the evolution of our botanical prescription drug pipeline, it is timely to develop our commercial and financial relationships both in North America and Asia,” said Dr. Andre Boulet, President and Chief Executive Officer of Devonian.

 

About the Conference

Held in the heart of the GTA’s Chinese community, the Global Chinese Financial Forum (GCFF) Toronto Conference 2017 will bring together the Chinese investors and public companies, market experts and financial service providers for one day of networking, presentations and knowledge sharing. With continued activity in the growing life science and tech sectors, the market is ripe with opportunities to invest. The conference will showcase investment opportunities in key sectors of Life Science, Technology, Mining and Oil & Gas.

 

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus traditional prescription medicines. Devonian is based on a broad-based platform originating from over ten years of research. This platform provides a unique process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX). “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory and anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments as well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

For more information about Devonian Health Group Inc., visit www.groupedevonian.com.

 

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Contact:
André Boulet
President and Chief Executive Officer
Devonian Health Group inc.
Telephone: (514) 248-7509
Email: apboulet@groupedevonian.com